| Dr Patrick Ryan Marcello, DMD | |
|
103a Regency Commons Dr, Greer, SC 29650-5210 | |
| (864) 801-8877 | |
| (864) 801-8897 |
| Full Name | Dr Patrick Ryan Marcello |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 103a Regency Commons Dr, Greer, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225185226 | NPI | - | NPPES |
| ZX3609 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 3609 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick Ryan Marcello, DMD 103a Regency Commons Dr, Greer, SC 29650-5210 Ph: (864) 801-8877 | Dr Patrick Ryan Marcello, DMD 103a Regency Commons Dr, Greer, SC 29650-5210 Ph: (864) 801-8877 |
News Archive
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
A newly published study by researchers from the University of Colorado School of Medicine has identified a potential therapeutic target for treating obesity and diabetes.
Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.
› Verified 7 days ago
Jonathan Elliot Fryml, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 318 Memorial Dr, Greer, SC 29650 Phone: 864-416-7880 Fax: 864-416-7808 | |
Dr. Natalie Jane Horton Simpson, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 319 The Parkway, Ste A, Greer, SC 29650 Phone: 864-968-1777 Fax: 864-968-0827 | |
Kathleen W Monn, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 420 The Parkway, Ste B, Greer, SC 29650 Phone: 864-877-3232 Fax: 864-877-3773 | |
Mrs. Yanina A Cox, D.M.D Dentist Medicare: Medicare Enrolled Practice Location: 103a Regency Commons Dr, Greer, SC 29650 Phone: 864-801-8877 Fax: 864-801-8897 | |
Dr. Marc D Workman, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 114 Father Hugo Dr, Greer, SC 29650 Phone: 864-907-1122 | |
Mark V Muncy, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 420 The Parkway, Ste B, Greer, SC 29650 Phone: 864-877-3232 Fax: 864-877-3773 |